PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals financial challenges, with cash reserves declining and significant net losses due to increased R&D expenses. While there is optimism about dystrophin levels in trials, uncertainties exist regarding patient recruitment and trial timelines. The Q&A section highlights operational and scientific risks, with management providing vague responses on key timelines and regulatory endpoints. Despite potential positive outcomes in therapy development, the financial strain and lack of clear guidance create a negative sentiment. The absence of a market cap further complicates the assessment, leading to a prediction of a negative stock price movement.
Key Financial Performance
Cash and Cash Equivalents $110.4 million as of December 31, 2023, down from $181.8 million as of December 31, 2022.
Net Loss (Q4 2023) $19.5 million for the fourth quarter of 2023.
Net Loss (Full Year 2023) $78.6 million for the full year 2023.
Research and Development Expenses (Q4 2023) $16.3 million for the three months ended December 31, 2023, an increase attributed to costs associated with the advancement of PGN-ED051 and PGN-EDODM1 programs.
Research and Development Expenses (Full Year 2023) $68.1 million for the full year 2023.
General and Administrative Expenses (Q4 2023) $4.5 million for the three months ended December 31, 2023, attributed to an increase in personnel-related costs.
General and Administrative Expenses (Full Year 2023) $16.6 million for the full year 2023.
Shares Outstanding Approximately 32.4 million shares outstanding as of February 29, 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Initiation of first inpatient clinical trials for PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) programs.
Clinical Trials: Completed enrollment for cohort 1 in CONNECT1-EDO51 and received clearance from MHRA for CONNECT2-EDO51.
Fast Track Designation: EDODM1 granted fast track designation by FDA to expedite development.
Preclinical Programs: Advancing PGN-EDO53, targeting exon 53 of dystrophin transcript.
Market Expansion: Plans to open trial sites for CONNECT2 in the U.S. and other geographies.
Geographic Expansion: Initiating dosing in the UK for CONNECT2-EDO51 in Q3 2024.
Financial Position: Net proceeds from stock offering extend cash runway into 2026.
Research and Development Expenses: R&D expenses for 2023 were $68.1 million, primarily for PGN-ED051 and PGN-EDODM1.
Strategic Shift: Focus on developing potentially transformative medicines for neuromuscular diseases.
Regulatory Strategy: Plans for accelerated approval based on safety and dystrophin expression data.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces regulatory uncertainties as it seeks approvals for its clinical programs, particularly with the FDA and MHRA. The need for alignment with regulatory authorities for potential accelerated approvals adds complexity to their development timelines.
Clinical Trial Risks: There are inherent risks associated with clinical trials, including the possibility of adverse safety data emerging from ongoing trials, which could delay or halt progress in the development of EDO51 and EDODM1.
Financial Risks: Despite a recent stock offering that raised approximately $80 million, the company reported a net loss of $19.5 million for Q4 2023 and $78.6 million for the full year, indicating ongoing financial pressures that could impact future operations.
Competitive Pressures: PepGen operates in a competitive landscape for neuromuscular disease treatments, with the potential for other companies to develop similar or superior therapies, which could affect market share and pricing.
Supply Chain Challenges: The advancement of clinical programs is dependent on the supply chain for manufacturing and distributing their therapies, which could face disruptions that impact timelines and costs.
Market Access Risks: Even with successful clinical trials, there is no guarantee of market access or reimbursement for their therapies, which could limit the commercial viability of their products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Programs Initiation: Initiated first inpatient clinical trials for DMD and DM1 using EDO platform.
Financial Position: Recent stock offering provides strong financial position, extending cash runway into 2026.
DMD Program Details: Completed enrollment for cohort 1 in CONNECT1-EDO51; plans to escalate dosing based on safety data.
DM1 Program Updates: FDA lifted clinical hold on EDODM1; fast track designation received.
Preclinical Development: Advancing PGN-EDO53 for DMD targeting exon 53.
Cash Projections: Current cash and equivalents expected to fund operations into 2026.
Net Loss: Net loss for Q4 2023 was $19.5 million; full year loss was $78.6 million.
R&D Expenses: R&D expenses for Q4 2023 were $16.3 million; full year expenses were $68.1 million.
Upcoming Data Announcements: Preliminary data from CONNECT1-EDO51 expected mid-2024; FREEDOM-DM1 data in second half of 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Offering: On February 9, 2024, PepGen successfully completed an underwritten stock offering of 7.53 million common shares for gross proceeds of approximately $80 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk a little bit more about the mechanism of PGN-EDODM1?
A:Our mechanism targets the CUG repeat, liberating MBNL1 and reducing toxic foci in patient cells, correcting splicing and myotonia in mouse models.
Q:Are the dystrophin measures unadjusted? How much above 1% dystrophin do we need to see initial readout?
A:We are looking for at least a 1% gain over background dystrophin levels at the 5 mg per kg dose, which gives us confidence for higher levels at 10 mg per kg.
Q:Have you started identifying patients for the 10 mg per kg cohort? Will data from this cohort be available this year?
A:We anticipate robust recruitment for the CONNECT1 study and will provide updates on the timing of the 10 mg per kg data readout.
Q:Can you discuss the preliminary kinetics and pace of exon skipping?
A:We expect to see high levels of exon skipping by dose 4, with potential for robust dystrophin production.
Q:What is a meaningful level of splicing correction? What functional assessments will be included in FREEDOM1?
A:We believe over 25% splicing correction is necessary for robust physiological changes. FREEDOM1 will assess myotonia, strength, and other functional measures.
Q:What does the recent SRP-5051 data tell you about your program?
A:EDO51 showed six-fold higher exon skipping compared to SRP-5051, indicating potential for greater dystrophin production.
Q:What is your take on the agency's view on primary endpoints in the DM1 program?
A:Conversations with regulators are ongoing; we believe splicing correction will correlate with myotonia correction.
Q:Review of Unclear Management Responses
A:Management did not provide a clear answer regarding the agency's view on primary endpoints for the DM1 program, stating that discussions are ongoing without specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO
CTA
Chief Staff
DMD exon
DSMB
EU
FREEDOM Phase
FREEDOM study
FREEDOM trial
II trial
Phase II
UK
animal
authority
background
cohort EDO
cohort mg
correction myotonia
designation
disease
dystrophin patient
exon approach
exon human
exon therapy
level myotonia
level protein
level splicing
mg cohort
mg dose
model level
modeling work
moment
myotonia correction
nonhuman primate
offering
outcome measure
review
sense
splicing correction
strength
trial DMD
trial boy
vHoT
PEPG Transcript
PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript
Unknown3-7
The earnings call reveals financial challenges, with cash reserves declining and significant net losses due to increased R&D expenses. While there is optimism about dystrophin levels in trials, uncertainties exist regarding patient recruitment and trial timelines. The Q&A section highlights operational and scientific risks, with management providing vague responses on key timelines and regulatory endpoints. Despite potential positive outcomes in therapy development, the financial strain and lack of clear guidance create a negative sentiment. The absence of a market cap further complicates the assessment, leading to a prediction of a negative stock price movement.
PepGen Inc (PEPG) Q4 2022 Earnings Call Transcript
Neutral3-25
PEPG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
